Gelesis Holdings, Inc.
GLSHQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.63M
Close$
Share Statistics
| Market cap | $11.63 Million |
|---|---|
| Enterprise Value | $63.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.35 |
| Beta | 0.62 |
| Outstanding Shares | 73,334,861 |
Return
| Return on Equity | 270.56% |
|---|---|
| Return on Assets | -52.56% |
| Return on Invested Capital | -343.14% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 5.24 |
| Enterprise Value to EBIT | -0.96 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.94 |
| Debt to Equity | -3.21 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
$3.74 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gelesis Holdings Inc
2 employees
CEO: Alessandro Sannino Gelesis Holdings, Inc. operated as a commercial-stage biotherapeutics company, concentrating on the development of biomimetic solutions. Its core mission revolved around addressing the root causes of obesity and various chronic gastroint...